Consistent FFP2-masking as part of reducing viral respiratory infections on medical wards for allogeneic hematopoietic stem cell transplantation by T. Richardson, D. Schütte, K. Feyer, L. Grass, M. Hallek, C. Scheid, F. Simon, T. Braun, M. Fürstenau, P. Gödel, U. Holtick

Get full text

Author Correction: Consistent FFP2-masking as part of reducing viral respiratory infections on medical wards for allogeneic hematopoietic stem cell transplantation by T. Richardson, D. Schütte, K. Feyer, L. Grass, M. Hallek, C. Scheid, F. Simon, T. Braun, M. Fürstenau, P. Gödel, U. Holtick

Get full text

P681: EUROFLOW STANDARDIZATION TECHNIQUE AND NORMALIZATION PROCEDURES IN LONGITUDINAL FLOW CYTOMETRIC EXPRESSION ANALYSIS OF CD20 IN CLL PATIENTS RECEIVING ANTI-CD20 DIRECTED THERA... by P. J. Walter, A. Schilhabel, P. Cramer, J. von Tresckow, S. Kohlscheen, K. Fischer, B. Eichhorst, S. Böttcher, M. Brüggemann, M. Kneba, M. Hallek, M. Ritgen

Get full text

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY by O. Al-Sawaf, C. Zhang, S. Robrecht, A. Kotak, N. Chang, A.-M. Fink, E. Tausch, C. Schneider, M. Ritgen, K.-A. Kreuzer, B. Chyla, B. Eichhorst, Y. Jiang, S. Stilgenbauer, M. Hallek, K. Fischer

Get full text

P1184: PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT by P. Borchmann, A. Lohneis, P. Gödel, H. Balke-Want, C. Schmid, F. Ayuk, S. Holtkamp, L. Hanssens, G. Zadoyan, B. Friedrichs, M. Assenmacher, I. Bürger, D. Schneider, T. Overstijns, C. Scheid, U. Holtick, S. Miltenyi, M. Hallek

Get full text

P1249: INHIBITION OF THE PENTOSE-PHOSPHATE-PATHWAY (PPP) MEDIATES MACROPHAGE REPROGRAMMING FROM SUPPORTIVE BYSTANDER FUNCTION TOWARDS ANTIBODY-DEPENDENT LYMPHOMA CELL CLEARANCE AND... by A. Beielstein, E. Izquierdo-Alvarez, N. Nickel, S. Blakemore, D. Vorholt, S. Chawan, H.-H. Bartel, J. Wiederstein, R. Linke, R. Brinker, M. Michalik, C. R. Costa Picossi, A. Villasenor, C. Barbas, M. Krüger, M. Hallek, C. Pallasch

Get full text

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS by P. Cramer, M. Fürstenau, A. Giza, S. Robrecht, E. Tausch, C. Schneider, C.-M. Wendtner, M. Hoechstetter, J. Schetelig, S. Böttcher, P. Dreger, A.-M. Fink, P. Langerbeins, O. Al-Sawaf, K. Fischer, S. Stilgenbauer, B. Eichhorst, M. Hallek

Get full text

S146: VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: 6-YEAR FOLLOW-UP AND GENOMIC ANALYSES IN A PIVOTAL PHASE 2 TRIAL by S. Stilgenbauer, E. Tausch, A. W. Roberts, M. S. Davids, B. Eichhorst, M. Hallek, P. Hillmen, C. Schneider, S. Böttcher, R. Popovic, M. T. Ghanim, M. Moran, W. J. Sinai, X. Wang, N. Mukherjee, B. Chyla, W. G. Wierda, J. F. Seymour

Get full text

P652: MEASURING MINIMAL RESIDUAL DISEASE BEYOND 10-4 THROUGH IGHV LEADER-BASED NEXT GENERATION SEQUENCING IMPROVES PROGNOSTIC STRATIFICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA by P. Hengeveld, M. van der Klift, P. M. Kolijn, F. Davi, F. Kavelaars, E. de Jonge, S. Robrecht, J. Assmann, L. van der Straten, M. Ritgen, P. Westerweel, K. Fischer, V. Goede, M. Hallek, M.-D. Levin, A. Langerak

Get full text

S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB by O. Al-Sawaf, H. Y. Jin, C. Zhang, Y. Choi, S. Balasubramanian, S. Robrecht, A. Kotak, N. Chang, A.-M. Fink, E. Tausch, C. Schneider, M. Ritgen, K.-A. Kreuzer, B. Chyla, J. Paulson, B. Eichhorst, S. Stilgenbauer, Y. Jiang, M. Hallek, K. Fischer

Get full text